LENZ Therapeutics’ Presbyopia Therapy LNZ100 Accepted for FDA Review
LENZ Therapeutics, Inc. (NASDAQ: LENZ), a US-based biopharmaceutical company, has announced that the US Food...
Drug
AstraZeneca’s Wainzua Earns CHMP Nod for hATTR-PN Treatment in the EU
UK pharmaceutical juggernaut AstraZeneca (AZ, NASDAQ: AZN) has announced that Wainzua (eplontersen), an RNA-targeted therapy...
Novo Nordisk’s Semaglutide Shows 14% Reduction in Cardiovascular Events in Landmark SOUL Trial
Copenhagen-based healthcare giant Novo Nordisk (NYSE: NVO) has declared the primary outcomes of the SOUL...
AstraZeneca’s Saphnelo Approved for Use in Guangdong Under ‘Hong Kong-Macau Drug Access’ Policy
AstraZeneca (AZ, NASDAQ: AZN), a leading UK pharmaceutical company, has announced that its drug Saphnelo...
BeiGene’s Tevimbra Receives CHMP Recommendation for Expanded Use in G/GEJ and ESCC Cancers in EU
BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235), a leading China-based biotechnology company, has received...
Olymvax Bio Receives NMPA Approval for Clinical Study of Trivalent Influenza Vaccine
Olymvax Biopharmaceuticals Inc. (SHA: 688319), a leading vaccine specialist headquartered in Chengdu, has announced that...
Guangzhou Releases First Batch of Innovative Drugs and Medical Devices List, Featuring Local Companies
The Guangzhou Municipal Industry and Information Technology Bureau has unveiled the first batch of innovative...
Sino Biopharmaceutical’s Anlotinib Receives Ninth Indication Approval from China’s CDE for Soft-Tissue Sarcoma
Sino Biopharmaceutical Ltd (HKG: 1177), a leading pharmaceutical company in China, has announced that it...
Johnson & Johnson’s Akeega Approved in China as First Dual Action Tablet for mCRPC
Johnson & Johnson (J&J, NYSE: JNJ), a leading US pharmaceutical company, has announced that China’s...
Everest Medicines’ Nefecon Approved in Taiwan for Primary IgAN Treatment
Everest Medicines (HKG: 1952), a China-based pharmaceutical company, has announced that it has received market...
BeiGene’s Tevimbra Approved in China for NSCLC Patients as Neoadjuvant and Adjuvant Therapy
BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235), a leading China-based biotechnology company, has announced...
Novo Nordisk’s Alhemo Receives CHMP Recommendation for Haemophilia Prophylaxis in Europe
Novo Nordisk (NYSE: NVO), a Danish pharmaceutical company, has been notified that the Committee for...
Novartis’s Kisqali Receives Positive CHMP Opinion for Early Breast Cancer Treatment in the EU
Novartis (NYSE: NVS), the Swiss pharmaceutical giant, has announced that the Committee for Medicinal Products...
Kanghong Pharmaceutical’s NASH Drug KH629 Approved for Clinical Trials in China
Chengdu Kanghong Pharmaceutical Group Co., Ltd (SHE: 002773), a Chinese pharmaceutical company, has announced that...
Huadong Medicine Gets Green Light for HPK1 PROTAC Drug HDM2006 in Advanced Solid Tumors
Huadong Medicine Co., Ltd (SHE: 000963), a Chinese pharmaceutical company, has announced that it has...
Astellas Pharma’s Vyloy Receives FDA Approval for Gastric Cancer Treatment in CLDN18.2 Positive Tumors
Astellas Pharma Inc. (TYO: 4503), a Japanese pharmaceutical company, has announced that it has received...
Gilead Sciences to Withdraw Accelerated Approval of Trodelvy in Urothelial Carcinoma
Gilead Sciences Inc., (NASDAQ: GILD), a leading US-based biopharmaceutical company, has announced its intention to...
Jiangsu Hengrui Pharmaceuticals Initiates Phase III Clinical Trial for SHR-A1904 in Gastric Cancer
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has...
Jacobio Pharma’s G12C Inhibitor Gecirasib Earns Orphan Drug Designation in Europe for Pancreatic Cancer
Jacobio Pharma (HKG: 1167), a China-based biopharmaceutical company, has announced that it has received Orphan...
MicroPort NeuroTech’s NUMEN Silk Receives FDA Approval for Embolization Treatment
MicroPort NeuroTech Limited (HKG: 2172), a Chinese medical device company, has announced that it has...